Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-modal gradual fusion transformer-based model for predicting immunotherapy response in patients with hepatocellular carcinoma.

Journal of advanced research·2026

Same author

A machine learning-derived polygenic risk score reveals that healthy lifestyle counteracts obesity-related mortality.

NPJ digital medicine·2026

Same author

Metabolomic characterization of frailty identifies subtype-specific management strategies.

NPJ digital medicine·2025

Same author

Response to the Comment on "Development and Validation of a Machine Learning-Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease".

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Same author

Deep learning-empowered low-cost portable automated refraction system: A solution to the inadequate effective correction rate of refractive errors in resource-limited areas.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2025

Same author

Enhancing perceptual consistency and calibrating uncertainty for real-time table tennis ball detection.

Scientific reports·2025

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers.

Peishuang Xu¹, Chang Hong¹, Li Liu¹

¹Department of Health Management, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Biochimica Et Biophysica Acta. Reviews on Cancer

|April 25, 2025

Summary

This summary is machine-generated.

Identifying biomarkers is key to improving immunotherapy response rates for hepatocellular carcinoma (HCC) patients. This review covers immune checkpoint inhibitors (ICIs), combination therapies, and predictive markers for HCC treatment outcomes and adverse events.

Keywords:

Biomarkers Hepatocellular carcinoma Immune checkpoint inhibitor Immunotherapy PD-1 PD-L1

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 14, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Area of Science:

Hepatocellular carcinoma (HCC) research
Immunotherapy and cancer treatment
Biomarker discovery

Background:

Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, often diagnosed at advanced stages.
Traditional treatments like targeted therapies (sorafenib, lenvatinib) have limitations.
Immunotherapy, especially immune checkpoint inhibitors (ICIs), shows promise but not all HCC patients benefit.

Purpose of the Study:

To review the current research on immunotherapy, including ICIs and combination regimens, for HCC.
To summarize clinical and tumor markers that predict immunotherapy outcomes in HCC.
To outline markers for immune-related adverse events and discuss future research directions.

Main Methods:

Comprehensive literature review of immunotherapy for HCC.
Analysis of clinical indicators and tumor markers for treatment prediction.
Identification of markers for immune-related adverse events.

Main Results:

Immunotherapy, including ICIs and combination therapies, is a significant advancement in HCC treatment.
Various clinical and tumor markers are emerging for predicting patient response to immunotherapy.
Predictive markers for immune-related adverse events are also being identified.

Conclusions:

Identifying predictive markers is crucial for optimizing immunotherapy selection and improving treatment response rates in HCC patients.
Further research is needed to validate these markers and advance HCC immunotherapeutic strategies.